STAT+: Medicare is urged to monitor how rebates affect Part D drug spending, but agency demurs
STAT
SEPTEMBER 14, 2023
At issue is the opaque pharmaceutical pricing system. To win coveted placement on formularies – the list of medicines covered by insurers – drug companies pay rebates to Medicare Part D and commercial health plans. As the Government Accountability Office noted in its report , it’s complicated.
Let's personalize your content